RSV (Respiratory syncytial virus, respiratory syncytial virus) is a member of the pneumovirus subfamily of the Paramyxoviridae family. The virus is a common viral pathogen of respiratory tract infections. It can be distributed or erupted, local epidemic and widespread epidemic. It is a common and frequently-occurring disease in humans, especially… Continue Reading Natural whole human RSV antibody is expected to “treat” respiratory syncytial virus infection
On June 24th, NodThera, an entrepreneurial team from the University of Cambridge in the United Kingdom, received $40 million in financing to advance the development of small-molecule NLRP3 inhibitors. This was NodThera’s second round of financing. This round of financing was led by Sofinnova Partners and 5 AM Ventures, followed… Continue Reading Cambridge Venture Team NodThera Completes $40 Million Financing, Takes Pfizer to Develop NLRP3 Inhibitors
Alzheimer’s disease (AD) has been associated with many infectious agents such as viruses, bacteria, and fungi. However, this area has been excluded from mainstream research. There are many reasons for this. As early as sixty years ago, Sjogrend et al. speculated that microbes are related to the pathological process… Continue Reading Can the virus induce Alzheimer’s disease?
Aspirin If there is a magic drug in the world, it must be aspirin. Aspirin, also known as acetylsalicylic acid, is a long-standing antipyretic analgesic that was born on March 6, 1899. It is different from the current western medicine. It doesn’t have five or six hundred molecular weights, and… Continue Reading There are only two “magic drug” in the world.
Vitamin D used to be called “vitamin” and is now called “D hormone.” The study found that vitamin D is not only involved in calcium and phosphorus metabolism, promotes bone development, but also has many potential functions, such as the prevention and treatment of cardiovascular disease, diabetes, autoimmune diseases, and… Continue Reading There are many functions of vitamin D, but few of them are reliable.
RET (rearranged during transfection) is a proto-oncogene, located on chromosome 10. The RET protein encoded by the RET gene is a receptor tyrosine kinase (RTK) present on the cell membrane and belongs to the cadherin superfamily. When the growth factor binds to the extracellular region of RET, it triggers a… Continue Reading A head-to-head contest against a new generation of star RET inhibitors: BLU-667 vs LOXO-292
The Colombian writer Marquez wrote several paragraphs in his “One Hundred Years of Solitude”: José Alkateo Buendia realized that insomnia had invaded the town and he called parents to tell them what they knew about amnesia. The people decided to take measures to prevent the disaster from expanding to… Continue Reading The mystery of Alzheimer’s disease
On June 16th, Novartis announced the 14-month follow-up data of Kymriah (tisagenlecleucel) in the critical Phase II JULIET study of adult relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at the EHA 2018 conference. The data shows that in 93 evaluable patients, the ORR at the 14th month was 52%,… Continue Reading The latest 14-month follow-up data of Kymriah treatment DLBCL: Complete remission rate 40%
On June 17th, BMS announced at the EHA 2018 annual meeting that phase II ELOQUENT-3 study reached the primary endpoint, Empititi (elotuzumab) combined with poloximatil and low-dose dexamethasone (EPd regimen) compared to using pomametide alone And dexamethasone (Pd regimen) can significantly improve progression-free survival in patients with relapsed or refractory… Continue Reading Empliciti has significant benefits in the treatment of multiple myeloma with a 46% lower risk of disease progression
On June 12, Lilly/AstraZeneca announced the termination of the global phase III project for the treatment of Alzheimer’s disease with lanabecestat (oral BACE inhibitor). Lilly and AstraZeneca reached an alliance to develop lanabecestat in 2014. Lilly is mainly responsible for clinical development work. AstraZeneca is mainly responsible for pharmaceutical production.… Continue Reading Another phase III drug for Alzheimer’s disease failed! BACE target failure rate exceeds 80%